This Study is intended to evaluate the safety and effectiveness of Ameparomo Capsules 250 mg under actual medical practice.
Observational Model: Cohort Time Perspective: Prospective
Target Follow-Up Duration
Sites of infection department, internal medicine, and other relevant departments.
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
Actual Enrollment (submitted: February 26, 2019)
Original Estimated Enrollment (submitted: February 9, 2016)
Actual Study Completion Date
December 21, 2018
Actual Primary Completion Date
December 21, 2018 (Final data collection date for primary outcome measure)
Patients with no history of using this product
No exclusion criteria are set out in this study.
Sexes Eligible for Study:
15 Years to 99 Years (Child, Adult, Older Adult)
Accepts Healthy Volunteers
Contact information is only displayed when the study is recruiting subjects
Listed Location Countries
Removed Location Countries
Other Study ID Numbers
Has Data Monitoring Committee
U.S. FDA-regulated Product
IPD Sharing Statement
Plan to Share IPD:
Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/da....
Pfizer CT.gov Call Center
FOR MORE INFORMATION
Contact a representative by phone, email, or visiting the study website. Please see the references below: